Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675721 | 1.00 | CTSS (0.47) | CTSSCTSKPSMB5CA2CA1 | |
| SCHEMBL29356656 | 0.83 | CTSK (0.48) | CTSSCTSKCA2CA1CA7 | |
| SCHEMBL23969575 | 0.83 | CTSK (0.48) | CTSSCTSKCA2CA1CA7 | |
| SCHEMBL6859297 | 0.78 | PSMB5 (0.58) | CTSSCTSKPSMB5CTSLCTSB | |
| SCHEMBL13829481 | 0.78 | PSMB5 (0.58) | CTSSCTSKPSMB5CTSLCTSB | |
| SCHEMBL13829468 | 0.78 | PSMB5 (0.58) | CTSSCTSKPSMB5CTSLCTSB | |
| SCHEMBL2938875 | 0.78 | PSMB5 (0.70) | PSMB5PSENEN | |
| SCHEMBL2674863 | 0.78 | PSMB5 (0.70) | PSMB5PSENEN | |
| SCHEMBL2676575 | 0.78 | PSMB5 (0.70) | PSMB5PSENEN | |
| SCHEMBL6702263 | 0.78 | PSMB5 (0.70) | PSMB5PSENEN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173128-B2 | Methods and compositions for inducing apoptosis in cancer cells with an anti-DR5 antibody | IRM LLC (BM) | 2012-05-08 | — | — | US | disclosed |
| EP-1576179-B1 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS | IRM LLC (BM) | 2010-09-15 | — | — | EP | disclosed |
| US-7229617-B2 | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC (BM) | 2007-06-12 | — | — | US | disclosed |
| US-20070128204-A1 | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC (BM) | 2007-06-07 | — | — | US | disclosed |
| EP-1576179-A4 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS | IRM LLC (BM) | 2007-06-06 | — | — | EP | disclosed |
| EP-1399468-B1 | 2-((N-(2-AMINO-3-(HETEROARYL OR ARYL)PROPIONYL)-AMINOACYL)-AMINO)-ALKYLBORONIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2006-02-15 | — | — | EP | disclosed |
| US-20050239716-A1 | 2-{[N-(2-amino-3-(heteroaryl or aryl) propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives | FURET PASCAL | 2005-10-27 | — | — | US | disclosed |
| EP-1576179-A2 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS | IRM LLC (BM) | 2005-09-21 | — | — | EP | disclosed |
| US-6933290-B2 | 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives | NOVARTIS AG (CH) | 2005-08-23 | — | — | US | disclosed |
| US-20050079172-A1 | Methods and compositions for inducing apoptosis in cancer cells | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-04-14 | — | — | US | disclosed |
| US-20040167337-A1 | 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives | NOVARTIS AG (CH) | 2004-08-26 | — | — | US | disclosed |
| WO-2004050895-A2 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER CELLS | IRM LLC (BM) | 2004-06-17 | — | — | WO | disclosed |
| EP-1399468-A1 | 2-((N-(2-AMINO-3-(HETEROARYL OR ARYL)PROPIONYL)-AMINOACYL)-AMINO)-ALKYLBORONIC ACID DERIVATIVES | Novartis AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002096933-A1 | 2-{[N-(2-AMINO-3-(HETEROARYL OR ARYL)PROPIONYL)-AMINOACYL]-AMINO}-ALKYLBORONIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167337-A1 | 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives | AADAT, BCAT1, BCAT2 | CTSS 3852/4885CTSK 3923/4885PSMB5 2583/4885 |
| US-20050239716-A1 | 2-{[N-(2-amino-3-(heteroaryl or aryl) propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives | AADAT, PIGS, SLC1A5 | CTSS 3505/4885CTSK 3671/4885PSMB5 1454/4885 |
| US-20050079172-A1 | Methods and compositions for inducing apoptosis in cancer cells | BAD, BAX, CASP3 | CTSS 3076/4885CTSK 2509/4885PSMB5 1425/4885 |
| US-20070128204-A1 | Methods and compositions for inducing apoptosis in cancer cells | BAD, BAX, BID | CTSS 2533/4885CTSK 1799/4885PSMB5 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.